Intrexon

The Food and Drug Administration says modified mosquitoes likely don't pose a threat, opening the door for field tests, the New York Times reports.

Into the Zika Fray

The New York Times profiles Randal Kirk, whose Intrexon bought Oxitec last summer.

The firm sold 5,609,756 shares of its common stock at $41 per share. Proceeds will be used for general corporate purposes and strategic acquisitions or investments.

The synthetic biology firm is offering about 4.9 million shares of its common stock at $41 per share. 

Intrexon seeks to buy the remaining 49 percent stake in the firm, which creates animal models of human diseases in miniature pigs. 

NEW YORK (GenomeWeb News) – Intrexon today announced an agreement to acquire adult stem cell technology firm Medistem for about $26 million.

NEW YORK (GenomeWeb News) – Reporting for the first time as a public company, synthetic biology company Intrexon said after the close of the market on Thursday that revenues in its third quarter more than doubled year over year.

NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon reported after the close of the market Thursday that its second quarter revenues jumped more than 150 percent year over year as the firm trimmed its loss.

NEW YORK (GenomeWeb News) – Investment bank Mizuho Securities today initiated coverage of synthetic biology firm Intrexon with a Buy rating and a price target on the company's shares of $30.

NEW YORK (GenomeWeb News) – Intrexon announced after the close of the market on Tuesday the closing of its initial public offering raising $184 million in gross proceeds.

Pages

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.